Vivian Laquer

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Andrew Blauvelt, Kim Papp, Alice B. Gottlieb et al. · British Journal of Dermatology · 2019 · 172 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Shawn G. Kwatra, Gil Yosipovitch, Franz J. Legat et al. · New England Journal of Medicine · 2023 · 166 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg et al. · JAMA Dermatology · 2023 · 143 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

Andrew Blauvelt, Richard G. Langley, J.‐P. Lacour et al. · Journal of the American Academy of Dermatology · 2022 · 75 citations · Full text

Life Sciences, Dermatology, Immunology +16

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

Linda Stein Gold, Diamant Thaçi, Jacob P. Thyssen et al. · American Journal of Clinical Dermatology · 2023 · 67 citations · Full text

Life Sciences, Dermatology, Immunology +17